Kexing Biopharm Valuation

Q: What is the Fair Price of 688136 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688136 (CN¥16.56) is trading above our estimate of [[fair value]] (CN¥5.75)

Is 688136 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688136 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688136 (CN¥16.56) is trading above our estimate of fair value (CN¥5.75)

Significantly Below Fair Value: 688136 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688136?

Key metric: As 688136 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688136. This is calculated by dividing 688136's market cap by their current revenue.
What is 688136's PS Ratio?
PS Ratio	2.5x
Sales	CN¥1.33b
Market Cap	CN¥3.27b

688136 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	683.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 688136's PS Ratio compare to its peers?

The above table shows the PS ratio for 688136 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.5x
603739 Qingdao Vland Biotech	2.6x	8.6%	CN¥3.3b
300683 Wuhan Hiteck Biological PharmaLtd	5.7x	n/a	CN¥3.5b
300653 Yantai Zhenghai Biotechnology	9.9x	14.7%	CN¥3.8b
688319 Chengdu Olymvax Biopharmaceuticals	7.9x	21.7%	CN¥4.2b
688136 Kexing Biopharm	2.5x	27.9%	CN¥3.3b

Price-To-Sales vs Peers: 688136 is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (6.5x).

Price to Sales Ratio vs Industry

How does 688136's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
603716 Thalys Medical Technology Group	0.8x	n/a	US$211.90m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 688136 is good value based on its Price-To-Sales Ratio (2.5x) compared to the CN Biotechs industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is 688136's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688136 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.5x
Fair PS Ratio	5.9x

Price-To-Sales vs Fair Ratio: 688136 is good value based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (5.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%